One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
NCT ID: NCT01471405
Last Updated: 2019-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
54 participants
OBSERVATIONAL
2012-01-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
NCT00690898
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT02807233
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
NCT00517491
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
NCT02493517
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject or in case of subject's death next of kin having given their written informed consent prior to collection of the data by the sponsor (if locally required)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
III. Interní klinika Karlova Univerzita
Prague, , Czechia
CHU de Rouen
Bois-Guillaume, , France
Groupement hôspitalier est Federation d'endocrinologie.
Bron, , France
CHU Michallon
Grenoble, , France
Hôpital Claude Huriez
Lille, , France
CHU Timone
Marseille, , France
Hôpital Bicêtre
Paris, , France
Hôpital Haut Leveque
Pessac, , France
CHU de Reims
Reims, , France
Hôpital Larrey
Toulouse, , France
Universität Duisburg-Essen
Essen, , Germany
Klinikum der Johann Wolfgang, Goethe-Universität
Frankfurt, , Germany
Università Federico II di Napoli
Napoli, , Italy
Università Cattolica del Sacro Cuore
Roma, , Italy
İstanbul Universitesi, Cerrahpaşa Tıp Fakültesi
Istanbul, , Turkey (Türkiye)
Aberdeen Royal Infirmary
Aberdeen, , United Kingdom
Christie Hospital
Manchester, , United Kingdom
Derriford Hospital
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
2-79-52030-207 (NCT00690898)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
8-79-52030-742
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.